Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 4894 |
| PDBID: | 7SJN |
| Chains: | FG_C |
| Organism: | Homo sapiens |
| Method: | EM |
| Resolution (Å): | 3.40 |
| Reference: | 10.1038/s41467-022-32760-9 |
| Antibody | |
| Antibody: | 15H6.v4 Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | Galegenimab(Phase-II) |
| Antigen | |
| Antigen: | Synthetic construct HTRA1-LoopA peptide |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Heavy Chain: F
Mutation: NULL
| >7SJN_F|Chain D, F, H|Fab15H6.v4 Heavy Chain|Homo sapiens (9606) EVQLVQSGAEVKKPGASVKVSCKASGYKFTDSEMHWVRQAPGQGLEWIGGVDPETEGAAYNQKFKGRATITRDTSTSTAYLELSSLRSEDTAVYYCTRGYDYDYALDYWGQGTLVTV |
Light Chain: G
Mutation: NULL
| >7SJN_G|Chain E, G, I[auth L]|Fab15H6.v4 Light Chain|Homo sapiens (9606) DIQMTQSPSSLSASVGDRVTITCRASSSVEFIHWYQQKPGKAPKPLISATSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSAPWTFGQGTKVEIK |
Antigen
Chain: C
Mutation: NULL
| >7SJN_C|Chain A, B, C|Serine protease HTRA1|Homo sapiens (9606) DPNSLRHKYNFIADVVEKIAPAVVHIELFRKLPFSKREVPVASGSGFIVSEDGLIVTNAHVVTNKHRVKVELKNGATYEAKIKDVDEKADIALIKIDHQGKLPVLLLGRSSELRPGEFVVAIGSPFSLQNTVTTGIVSTTQRGGKELGLRNSDMDYIQTDAIINYGNSGGPLVNLDGEVIGINTLKVTAGISFAIPSDKIKKFLTES |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| Chain residues position delta_SASA
: residuesposition F: ASP31 SER32 GLU33 HIS35 TRP47 GLY50 ASP52 GLU54 THR55 ALA59 GLY99 TYR100 ASP101 TYR102 ASP103 TYR104 LEU106 G: TRP90 SER92 TRP95 C: ARG190 LYS191 LEU192 PRO193 PHE194 SER195 LYS196 ARG197 VAL199 LYS225 HIS226 ARG227 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 6 Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 6 Å from any atom.
Interacting residues (Atom distance based)
